| Literature DB >> 34884226 |
Katarzyna Karczewska1, Szymon Bialka2, Jacek Smereka3,4, Maciej Cyran4,5, Grazyna Nowak-Starz6, Jaroslaw Chmielewski7, Michal Pruc4, Pawel Wieczorek4,8, Frank William Peacock9, Jerzy Robert Ladny10, Lukasz Szarpak4,11.
Abstract
The available meta-analyses have inconclusively indicated the advantages of video-laryngoscopy (VL) in different clinical situations; therefore, we conducted a systematic review and meta-analysis to determine efficacy outcomes such as successful first attempt or time to perform endotracheal intubation as well as adverse events of VL vs. direct laryngoscopes (DL) for double-lumen intubation. First intubation attempt success rate was 87.9% for VL and 84.5% for DL (OR = 1.64; 95% CI: 0.95 to 2.86; I2 = 61%; p = 0.08). Overall success rate was 99.8% for VL and 98.8% for DL, respectively (OR = 3.89; 95%CI: 0.95 to 15.93; I2 = 0; p = 0.06). Intubation time for VL was 43.4 ± 30.4 s compared to 54.0 ± 56.3 s for DL (MD = -11.87; 95%CI: -17.06 to -6.68; I2 = 99%; p < 0.001). Glottic view based on Cormack-Lehane grades 1 or 2 equaled 93.1% and 88.1% in the VL and DL groups, respectively (OR = 3.33; 95% CI: 1.18 to 9.41; I2 = 63%; p = 0.02). External laryngeal manipulation was needed in 18.4% cases of VL compared with 42.8% for DL (OR = 0.28; 95% CI: 0.20 to 0.40; I2 = 69%; p < 0.001). For double-lumen intubation, VL offers shorter intubation time, better glottic view based on Cormack-Lehane grade, and a lower need for ELM, but comparable first intubation attempt success rate and overall intubation success rate compared with DL.Entities:
Keywords: double-lumen tube; endotracheal intubation; meta-analysis; one-lung ventilation; randomized controlled trials; systematic review
Year: 2021 PMID: 34884226 PMCID: PMC8658072 DOI: 10.3390/jcm10235524
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Database search and selection of studies according to PRISMA guidelines.
Summary characteristics of the included studies.
| Study | Country | Study Design | Intubation Method | No. of | Age | Sex, Male | BMI | ASA |
|---|---|---|---|---|---|---|---|---|
| Bakshi et al., 2019 | India | RCT | McGrath | 37 | 46.9 (17) | 25 (67.6%) | 21.8 (3) | 37 (100%) |
| Macintosh | 37 | 49.8 (16) | 23 (62.2%) | 23.0 (3) | 37 (100%) | |||
| Bensghir et al., 2010 | France | RCT | X-Lite | 34 | 41.8 (9) | 28 (82.3%) | 24 (2.9) | 34 (100%) |
| Macintosh | 34 | 44.6 (10) | 29 (85.3%) | 22.98 (2.19) | 34 (100%) | |||
| Chen et al., 2017 | China | RCT | Disposcope | 27 | 59.5 (12.9) | 9 (33.3%) | 24.3 (3.0) | NS |
| Macintosh | 27 | 61.0 (11.4) | 11 (40.7%) | 23.8 (3.1) | NS | |||
| El-Tahan et al., 2018 | Saudi Arabia | RCT | GlideScope | 34 | 39.9 (17.52) | 26 (76.5%) | NS | 20 (58.8%) |
| Airtraq | 35 | 33.8 (13.37) | 31 (88.6%) | NS | 19 (54.3%) | |||
| KingVision | 32 | 31.3 (14.8) | 27 (84.4%) | NS | 20 (62.5%) | |||
| Macintosh | 32 | 27.5 (9.83) | 19 (59.4%) | NS | 22 (68.8%) | |||
| Hamp et al., 2015 | Austria | RCT | Airtraq | 17 | 56.8 (10.6) | 9 (52.9%) | NS | 16 (94.1%) |
| Macintosh | 20 | 63.4 (9.3) | 11 (55.0%) | NS | 18 (90.0%) | |||
| Heir et al., 2018 | USA | RCT | ETView | 38 | NS | 28 (73.7%) | 29.8 | NS |
| Macintosh | 42 | NS | 19 (45.2%) | 27.0 | NS | |||
| Hsu et al., 2012 | Taiwan | RCT | GlideScope | 30 | 40.1 (18.7) | 7 (23.3%) | 21.3 (3.4) | 30 (100%) |
| Macintosh | 30 | 37.2 (15.4) | 11 (36.7%) | 23.0(5.6) | 30 (100%) | |||
| Hsu et al., 2013 | Taiwan | RCT | Trachway stylet | 30 | 40 (15) | 20 (66.7%) | 21 (4) | NS |
| Macintosh | 30 | 47 (15) | 22 (73.3%) | 23 (4) | NS | |||
| Huang et al., 2020 | China | RCT | GlideScope | 29 | 58.45 (8.8) | 11 (37.9%) | 23.33 (3.29) | 29 (100%) |
| C-MAC | 30 | 57.2 (9.6) | 18 (60.0%) | 22.82 (2.67) | 30 (100%) | |||
| Macintosh | 30 | 54.57 (11.78) | 20 (66.7%) | 24.32 (3.78) | 30 (100%) | |||
| Kido et al., 2015 | Japan | RCT | McGrath | 25 | 66.6 (11.3) | 15 (60.0%) | 22.3 (3.2) | 13 (52.0%) |
| Macintosh | 25 | 67.9 (15.0) | 16 (64.0%) | 21.9 (4.6) | 11 (44.0%) | |||
| Levy-Faber et al., 2015 | Izrael | RCT | VivaSight | 35 | 68 (61–74) | 21 (60.0%) | NS | 19 (54.3%) |
| Macintosh | 36 | 67 (61–75) | 18 (50.0%) | NS | 20 (55.6%) | |||
| Lin et al., 2012 | China | RCT | CEL-100 | 83 | 58.2 (9.6) | 55 (66.3%) | 22.9 (2.7) | 76 (91.6%) |
| Macintosh | 82 | 57.6 (9.4) | 52 (63.4%) | 23.1 (2.8) | 76 (92.7%) | |||
| Liu et al., 2018 | China | RCT | VivaSight | 26 | 39.5 (13.5) | 16 (61.5%) | 22.9 (3.1) | NS |
| Macintosh | 29 | 40.0 (13.3) | 18 (62.1%) | 23.6 (3.6) | NS | |||
| Maharaj et al., 2006 | Ireland | RCT | AirTraq | 30 | 43.8 (16.8) | 11 (36.7%) | 27.1 (6.1) | NS |
| Macintosh | 30 | 41.1 (16.9) | 11 (36.7%) | 27.7 (5.7) | NS | |||
| Mathew et al., 2021 | India | RCT | C-MAC | 44 | 36.3 | 29 (65.9%) | 22.1 | 42 (95.5%) |
| Macintosh | 43 | 40.4 | 28 (65.1%) | 22.5 | 39 (90.7%) | |||
| Onifade et al., 2020 | USA | RCT | VivaSight | 25 | 55.3 (6.6) | 11 (44.0%) | 27.5 (2.8) | 4 (16.0%) |
| Macintosh | 25 | 53.5 (5.2) | 13 (52.0%) | 28.7 (1.6) | 4 (16.0%) | |||
| Risse et al., 2020 | Germany | RCT | GlideScope | 34 | 66.3 (4.9) | 25 (73.5%) | 25.9 (1.4) | 10 (29.4%) |
| Macintosh | 31 | 59.3 (3.8) | 25 (80.6%) | 26.6 (1.9) | 10 (32.3%) | |||
| Russell et al., 2013 | Canada | RCT | GlideScope | 35 | 59 (12) | 15 (42.9%) | 26 (5) | 8 (22.9%) |
| Macintosh | 35 | 62 (14) | 18 (51.4%) | 26 (4) | 5 (14.3%) | |||
| Schuepbach et al., 2015 | Switzerland | RCT | VivaSight | 19 | 57 (17) | 9 (47.4%) | 23 (4) | 11 (57.9%) |
| Macintosh | 20 | 63 (10) | 10 (50.0%) | 24 (3) | 8 (40.0%) | |||
| Shah et al., 2016 | India | RCT | C-MAC | 30 | 54.57 (11.06) | 22 (73.3%) | NS | 30 (100%) |
| Macintosh | 30 | 52.13 (12.69) | 20 (66.7%) | NS | 30 (100%) | |||
| Wasem et al., 2013 | Germany | RCT | AirTraq | 30 | 63 (10) | 22 (73.3%) | 27.4 (2.8) | 16 (53.3%) |
| Macintosh | 30 | 55 (19) | 19 (63.3%) | 27.1 (6.2) | 17 (56.7%) | |||
| Xu et al., 2015 | China | RCT | SOS stylet | 30 | 50.1 (11.1) | 14 (46.7%) | 23.4 (3.0) | 26 (86.7%) |
| Macintosh | 30 | 46.3 (16.1) | 17 (56.7%) | 24.0 (4.9) | 27 (90.0%) | |||
| Yang et al., 2013 | Republic of Korea | RCT | Optiscope | 198 | 55.5 (9.7) | 140 (70.7%) | 23.2 (2.9) | NS |
| Macintosh | 199 | 56.5 (9.0) | 150 (75.4%) | 23.4 (3.1) | NS | |||
| Yao et al., 2015 | China | RCT | McGrath | 48 | 47.6 (13.8) | 33 (68.8%) | 22.0 (3.4) | 47 (97.9%) |
| Macintosh | 48 | 47.8 (16.3) | 33 (68.8%) | 21.9 (3.0) | 44 (91.7%) | |||
| Yi et al., 2013 | China | RCT | GlideScope | 35 | NS | NS | NS | NS |
| Macintosh | 35 | NS | NS | NS | NS | |||
| Yao et al., 2018 | Korea | RCT | McGrath | 22 | 47.5 (2.9) | 14 (63.6%) | NS | 22 (100%) |
| Macintosh | 22 | 49.3 (2.6) | 14 (63.6%) | NS | 22 (100%) |
Legend: NS: Not specified; RCT: Randomized controlled trial.
Figure 2Forest plot of first intubation attempt success rate among video-laryngoscope and direct-laryngoscope groups. The center of each square represents the weighted odds ratios for individual trials, and the corresponding horizontal line stands for a 95% confidence interval. The diamonds represent pooled results. Legend: CI = confidence interval; DL = direct laryngoscopy; OD = odds ratio; VL = video-laryngoscopy.
Figure 3Forest plot of time to intubation in video-laryngoscope and direct-laryngoscope groups. The center of each square represents the weighted mean differences for individual trials, and the corresponding horizontal line stands for a 95% confidence interval. The diamonds represent pooled results. Legend: CI = confidence interval; MD = mean difference.
Pooled analysis of adverse events reported in the included trials.
| Type of Adverse Event | No. of Studies | Events/Participants | Events | Heterogeneity between Trials | ||||
|---|---|---|---|---|---|---|---|---|
| VL | DL | RR | 95% CI | I2
| ||||
| Oral bleeding | 10 | 35/400 | 52/373 (13.9%) | 0.67 | 0.37 to 1.20 | 0.14 | 34% | 0.18 |
| Blood on laryngoscope blade | 5 | 10/180 | 10/176 | 0.93 | 0.33 to 2.65 | 0.29 | 19% | 0.90 |
| Bronchospasm | 5 | 0/162 | 4/163 | 0.19 | 0.02 to 1.60 | 0.97 | 0% | 0.13 |
| Sore throat | 15 | 149/640 | 174/549 | 0.86 | 0.67 to 1.09 | <0.001 | 79% | 0.22 |
| Hoarseness | 13 | 118/554 | 140/459 | 0.80 | 0.57 to 1.13 | <0.001 | 83% | 0.21 |
| Desaturation | 6 | 10/246 | 24/241 | 0.48 | 0.18 to 1.26 | 0.22 | 30% | 0.13 |
| Cardiac arrhythmia | 3 | 6/98 | 12/95 | 0.52 | 0.17 to 1.56 | 0.28 | 16% | 0.24 |
| Lip trauma | 3 | 4/170 | 1/98 | 2.07 | 0.34 to 12.76 | 0.57 | 0% | 0.43 |
| Dental trauma | 6 | 0/290 | 0/193 | NE | NE | NA | NA | NA |
| Esophageal intubation | 4 | 0/187 | 7/185 | 0.13 | 0.02 to 0.98 | 0.90 | 0% | 0.05 |
| Cuff rupture | 5 | 14/288 | 14/217 | 0.84 | 0.23 to 3.12 | 0.11 | 51% | 0.80 |
| Tube misplacement | 5 | 30/190 | 10/162 | 1.99 | 0.94 to 4.19 | 0.35 | 8% | 0.07 |
Legend: VL: video-laryngoscopy; DL: direct laryngoscopy; NE: not estimable; NA: not applicable; RR: risk ratio.